tbuckley/cabot-search huggingface dataset:
Should liver metastases of breast cancer be biopsied to improve treatment choice?
Authors: M. A. Locatelli, G. Curigliano, L. Fumagalli, V. Bagnardi, G. Aurilio, P. Della Vigna, L. Monfardini, S. Giudici, G. Viale, A. Goldhirsch
Journal: Journal of Clinical Oncology (2010)

CRA1008 Background: Decision making on systemic treatment of women with metastatic breast cancer is based on features like estrogen receptor (ER), progesterone receptor (PgR), and HER2 status assessed on the primary tumor. We evaluated the concordance of receptor status between primary tumor and liver metastases (mts) and its impact on treatment choice. Methods: We retrospectively analyzed a database including ultrasound guided liver biopsies performed from 1995 to 2008. All tissue samples, both from primary tumor and liver mts, were analyzed for ER, PgR and HER2 status. Clinical and biological data were obtained from medical charts. Differences between proportions were evaluated using the Pearson chi-square test. Results: We identified 255 consecutive patients (pts) with matched primary and liver tissue samples. Median time from primary diagnosis to liver biopsy was 3.4 years (range 0-18.3 years). Changes in ER status were observed in 41/255 pts (16.0%). 16/58 pts (27.6%) changed from ER-negative to ER-positive and 25/197 pts (12.7%) changed from ER-positive to ER-negative (p=0.0066). Changes in PgR status were observed in 76/255 pts (29.8%). 18/91 pts (19.8%) changed from PgR-negative to -positive and 58/164 pts (64.6%) from PgR-positive to PgR-negative (p &lt;0.0001). 12/52 pts (23.1%) changed from ER- and PgR-negative to ER- or PgR-positive (group A) and 27/203 pts (13.3%) changed from ER- or PgR-positive to ER- and PgR-negative (group B) (p=0.087). In the group A the treatment of 4/12 pts (33.3%) was changed after biopsy: 2/4 started endocrine treatment (HT) and 2/4 stopped it. In group B the treatment of 18/27 pts (66.6%) was changed after biopsy: 17/18 stopped HT. Changes in HER2 status were observed in 22/167 pts (13.1%): 6/116 pts (5.1%) changed from HER2-negative to HER2-positive and 16/51 pts (31.4%) changed from HER2-positive to negative (p≤0.0001). In this group pts started and/or stopped a trastuzumab containing treatment after biopsy. Conclusions: There was a discordance in receptor status between primary tumor and liver mts, which led to change in therapy for 48/255 of pts (18.8%). Biopsy of metastases for reassessment of biological features should be considered in all pts when safe and easy to perform, since it is likely to impact treatment choice. No significant financial relationships to disclose.
Systemic Delivery of Nanoliposomal Ceramide Displays Anti-Leukemic Activity in a Rat Model of Large Granular Lymphocytic Leukemia
Authors: Xin Liu, Lindsay Ryland, Jun Yang, Cesar Aliaga, James Kaiser, Ranran Zhang, Kendall Thomas, Ruth Nancy Jarbadan, Joseph Hughes, Mark Kester, Thomas P. Loughran
Journal: Blood (2008)
A Plasmin Inhibitor Prevents Lethal Acute Graft-Versus-Host Disease in Mice
Authors: Aki Sato, Yoshihiko Tashiro, Chiemi Nishida, Ismael Gritli, Kaori Kusubata, Satoshi Takahashi, Beate Heissig, Koichi Hattori, Hiromitsu Nakauchi
Journal: Blood (2011)
Evolving trends in non-clear cell renal cell cancer (RCC) epidemiology: A large registry analysis of 4,483 patients.
Authors: Ashok P. Pai, Monica Brown, Chong-xian Pan, Primo Lara
Journal: Journal of Clinical Oncology (2012)

4607 Background: Non-clear cell (ncc) RCC is uncommon but includes a heterogeneous group of histologic subtypes such as papillary, chromophobe (Chr), medullary (Med), and collecting duct (CD) cancers. We used a large cancer registry to define nccRCC clinical features and outcomes, identify prognostic variables, and to generate hypotheses for further study. Methods: Invasive RCC tumors in the California Cancer Registry from 1998-2009 among adults &gt; 18 years of age (n=38,251) were analyzed. Baseline clinical and tumor variables were collected. Primary outcome measures were 3-year cause-specific (CSS) and overall survival (OS). Uni- and multivariate survival analysis were used to identify predictors of CSS and OS. Results: Of 38,251 RCC cases, 19,149 (50%) were of clear cell type; 14,619 (38.2%) were “unclassified.” Thus, 4,483 (11.7%) nccRCC cases were identified and included in this analysis. Of these, 3,304 (73.7%) were diagnosed in 2004-09, suggesting a shift to more precise coding of histologic subtypes starting in the early 2000s. Histology distribution (n, %): papillary - 2,863 (63.9%); Chr - 1,507 (33.6%); and other including Med and CD - 113 (2.5%). Variables associated with significantly better OS and CSS (univariate analysis) were Chr histology, female sex, and higher socioeconomic status (SES). Significantly worse OS and CSS were seen in Med+CD, age &gt; 65 yrs, no nephrectomy (Nx), and higher stage. Non-hispanic blacks had significantly worse OS and CSS, while the “targeted therapy era” (2004-2009) was associated with better OS. Multivariate analysis showed the following to be independently associated with outcomes (all p &lt;0.001; Hazard Ratios [HR] shown for CSS and OS): Chr histology (0.48, 0.56), Med+CD histology (2.99, 2.42), no Nx (2.84, 3.18), regional stage (5.84, 1.98), distant stage (25.7, 7.67); and non-hispanic blacks (1.5,2 p=0.006; 1.25, p=0.03). Age &gt; 65 yrs (HR 1.78, p&lt;0.001) and high SES (HR 0.88, p=0.001) were associated with OS but not CSS. Conclusions: This is among the largest registry analyses of nccRCC ever performed, showing emerging trends in this uncommon RCC subset. Clinical variables associated with CSS and OS were identified that can inform the design of future clinical trials in nccRCC.
Engineering a Valve-Regulated Endothelialized Microfluidic Device As an "in Vitro" Bleeding Time for Assessing Global Hemostasis
Authors: Yumiko Sakurai, Elaissa T. Hardy, Byungwook Ahn, Shannon L. Meeks, W. Hunter Baldwin, Shawn M Jobe, Wilbur A Lam
Journal: Blood (2015)
Prostate cancer screening and incidence among men younger than age 50.
Authors: J. Li, R. German, J. King, D. Joseph, T. Thompson, X. Wu, E. Tai, U. Ajani
Journal: Journal of Clinical Oncology (2011)

183 Background: Prostate cancer has long been considered as a disease of older men. However, age at diagnosis with prostate cancer has continued to decline. Since the introduction of prostate-specific antigen (PSA) test in 1986, the prostate cancer incidence rate has steadily and dramatically increased in men under age 50. This study aims to better understand demographic variations in prostate cancer screening and incidence, and clinical characteristics of prostate cancers in men under age 50. Methods: We examined prostate cancer testing data from the Behavioral Risk Factor Surveillance System (2002, 2004, 2006, and 2008) and prostate cancer incidence data from the CDC's National Program of Cancer Registries and the NCI's Surveillance, Epidemiology, and End Results programs (2001-2006). We estimated the weighted percentage of self-reported cancer testing using SUDAAN and age-adjusted cancer incidence rates and trends using SEER-STAT. Statistical significance for trends was determined by the annual percentage change (APC) differing form zero. Results: A total of 29,176 prostate cancer cases were identified from 2001-2006 among men under age 50. Of these, 551 (1.9%) were among men under age 40. Incidence rates remained stable from 2001-2006; however the incidence of well-differentiated tumors decreased significantly (APC=−24.7) during this time period. About 44% of men aged 40-49 years old reported having a prostate cancer test in the past two years. Prostate cancer testing and incidence rates were highest among men who were black, non-Hispanic, or lived in the northeast. Black men had more than a 2-fold increase in cancer incidence than white men. Conclusions: The magnitude of prostate cancer testing and incidence in men under age 50 reveals significant health/public health problems in this younger population. This study demonstrates substantial regional differences in prostate cancer testing and incidence in men under age 50. It also confirms that prostate cancer testing and incidence varies by race and ethnicity. We observed a large disparity in prostate cancer incidence between blacks and whites. The incidence rate remained stable over time; the dramatic decrease occurred in well-differentiated cancers. No significant financial relationships to disclose.
Anthropomorphic and hormone abnormalities in testicular cancer patients.
Authors: M. Singhera, J. Coffey, F. McDonald, A. Horwich, D. P. Dearnaley, E. Rapley, R. A. Huddart
Journal: Journal of Clinical Oncology (2011)

233 Background: Studies show a range of environmental and genetic associations with testicular cancer, specifically testicular dysgenesis, increased height, and multiple dysplastic naevi. To confirm these findings, we studied a cohort of testicular cancer patients and healthy controls. We also studied a cohort of unaffected relatives of patients to identify if any noted differences might be due to shared genetic/environmental background. Methods: We identified index cases from the hospital database. They nominated an unaffected relative and an unrelated friend. Controls were supplemented by recruitment of institutional staff. Results: 183 index cases (IC), 57 unaffected relatives (UR) and 103 unrelated controls (UC) were identified. Mean age was 47 years (25-78) IC, 44 years (18-74) in UR and 42 years (20-74) in UC. IC treated by chemotherapy (ch) had higher mean FSH than non chemotherapy patients (s)[18.98 v 13.22 (p=0.01)] and lower mean testosterone [ch:12.21, s:13.52 (p=0.04)] though mean LH [ch:7.94, s:6.05 (p=0.10)] and BMI (ch:27.38 s:26.81 (p=0.33) were not significantly different. Conclusions: In contrast to other studies, we found both testicular cancer patients and their relatives were shorter and with reduced arm length compared with controls; a sign of a possible shared genetic or environmental effect. There was no significant difference in weight, BMI, body fat %, lean body mass, and leg length. FSH and LH were significantly elevated and testosterone reduced in index cases (but not relatives) particularly in those who had chemotherapy. The lack of difference between relatives and controls suggests these are most in keeping with direct treatment effects. [Table: see text] No significant financial relationships to disclose.
Challenge and current status of night outpatient chemotherapy in our institution
Authors: Yoko Tokumitsu, Masahiko Motegi, Ichiro Naruse, Hisanori Shoji, Mika Takahashi, Kazue Hanyu, Tomomi Shimizu, Yoshitaka Ando, Kyoichi Kaira, Takayuki Asao
Journal: Annals of Oncology (2015)
Evidence-based indications for post-mastectomy radiation after neoadjuvant chemotherapy for stage II-III breast cancer.
Authors: J. Mayadev, B. Fowble, J. P. Einck, D. Kim, S. McCloskey, C. M. Yashar, S. L. Chen, S. E. Hwang
Journal: Journal of Clinical Oncology (2011)

114 Background: There are no established guidelines to define the role of post-mastectomy radiation therapy after neoadjuvant chemotherapy. We sought to identify a cohort of women with stage II-III breast cancer in whom radiation may be omitted based on the risk of local-regional failure (LRF). Methods: Seven breast cancer physicians participating in the multi-campus University of California (UC) Athena Breast Health Network identified, reviewed and abstracted the available literature (from MEDLINE and Cochrane databases), formulated evidence tables (endpoints LRF, disease-free, and overall survival) and developed a risk assessment table of women undergoing mastectomy after neoadjuvant chemotherapy. We created 18 hypothetical clinical case scenarios, and using the American College of Radiology appropriateness criteria methodology, assigned appropriateness ratings for post-mastectomy radiation for each scenario based on our literature review. Results: 23 of 24 studies identified were retrospective from single institutions. Consensus (80% agreement in a category) in the appropriateness rating was achieved for 78% of the clinical scenarios. Distinct LRF risk categories emerged. Patients who presented with clinical stage II (T1-2N0-1) ER(+) disease with age at diagnosis ≥35-40 years who had either a pathologic complete response (pCR) or 0-3 positive nodes without LVI or ECE were identified as having ≤10% risk of LRF without radiation. Limited data support pCR stage IIIA patients as being low risk. Conclusions: In the absence of randomized trial data, we identified existing data to guide the use of PMRT in the neoadjuvant chemotherapy setting. Using this data and the appropriateness ratings, we found a high concordance of treatment recommendations for PMRT in our clinical scenarios and were able to identify a cohort of women with a low risk of LRF without radiation. These women will form the basis for future clinical studies in the UC Athena Breast Health Network.
Romidepsin Synergizes with Lenalidomide in T Cell Lymphoma Cell Lines By Increasing Reactive Oxygen Species and Modulating PI3K/AKT and MAPK/ERK Signaling Pathways
Authors: Maria Cosenza, Monica Civallero, Stefania Fiorcari, Samantha Pozzi, Luigi Marcheselli, Stefano Sacchi
Journal: Blood (2014)
SIRPαFc, a CD47-Blocking Cancer Immunotherapeutic, Sensitizes Malignant B Cells to Macrophage-Mediated Destruction
Authors: Natasja Nielsen Viller, Saman Maleki Vareki, Karen Dodge, Hui Chen, Vivian Lee, Vien Chai, Xinli Pang, Mark Wong, Suzanne Trudel, Rene Figueredo, Macarena Pampillo, James Koropatnick, Penka S. Petrova, Robert A. Uger
Journal: Blood (2015)
Imaging Phenotyping Using Radiomics to Predict Micropapillary Pattern within Lung Adenocarcinoma
Authors: So Hee Song, Hyunjin Park, Geewon Lee, Ho Yun Lee, Insuk Sohn, Hye Seung Kim, Seung Hak Lee, Ji Yun Jeong, Jhingook Kim, Kyung Soo Lee, Young Mog Shim
Journal: Journal of Thoracic Oncology (2016)
Use of immunocytology to predict bladder cancer presence in patients with asymptomatic hematuria.
Authors: E. K. Cha, L. Tirsar, S. F. Shariat, P. J. Christos, M. Mazumdar, J. Hennenlotter, C. Schwentner, C. Mian, M. Lodde, B. J. Schmitz-Drager
Journal: Journal of Clinical Oncology (2011)

242 Background: The uCyt immunocytology assay detects cellular biomarkers for bladder cancer (BCa) in exfoliated urothelial cells. We assessed the performance of uCy for detecting BCa in patients undergoing initial evaluation for asymptomatic hematuria. Methods: Data from 1,182 subjects without a history of BCa undergoing evaluation for hematuria were collected at three centers: EuromedClinic/Urologie24, University of Tübingen, and Central Hospital of Bolzano. All subjects underwent standard workup (i.e., voided cytology, upper tract imaging, and cystoscopy) and immunocytology. Results: Overall, 245 subjects had BCa (20.7%). The sensitivity/specificity/negative predictive value for uCyt and cytology were 82.4%/86.6%/95.0% and 46.5%/94.9%/87.2%, respectively. uCyt (OR 18.3, p&lt;0.001) and cytology (OR 2.9, p&lt;0.001) were associated with BCa in a multivariable analysis. The base model (age, gender, smoking status, type of hematuria) predicted BCa with an accuracy of 74.1%. Addition of cytology to the base model improved predictive accuracy (PA) to 83.5% (p&lt;0.001), while addition of uCyt to the base model improved PA to 90.1% (p&lt;0.001). Addition of uCyt to Model 1 significantly improved PA (+7.6%, p&lt;0.001), but addition of cytology to Model 2 did not (+1.0%, p=0.057). uCyt performed equally well in patients with microscopic and gross hematuria (OR 30 vs. 27), while cytology did not (OR 18 vs. 12). Conclusions: uCyt is a strong, independent predictor of BCa in patients with hematuria; it outperforms cytology. uCyt may help with patient counseling, quality of care optimization (referral prioritization), and possibly sparing unnecessary hematuria workup in patients at extremely low risk of BCa. [Table: see text] No significant financial relationships to disclose.
Nitric Oxide Synthase - Nitric Oxide Involvement in the Human Neutrophil Free Radical Generation: Role of iNOS and Rac2 Interaction
Authors: Anupam Jyoti, Abhishek Singh, Ravi Keshari, Sachin Kumar, Rohit Saluja, Megha Dubey, Anupam Verma, Virendra Bajpai, M K Barthwal, Anil K Tripathi, Madhu Dikshit
Journal: Blood (2012)
Impact of chemotherapy timing on local-regional failures in patients with breast cancer undergoing breast-conserving therapy.
Authors: E. A. Mittendorf, T. A. Buchholz, S. L. Tucker, F. Meric-Bernstam, H. M. Kuerer, A. M. Gonzalez-Angulo, I. Bedrosian, G. Babiera, M. Yi, M. I. Ross, G. N. Hortobagyi, K. Hunt
Journal: Journal of Clinical Oncology (2011)

82 Background: Debate continues as to whether BCT after neoadjuvant chemotherapy (chemo) can achieve long-term local control rates similar to those experienced by patients undergoing surgery first, especially in those presenting with large tumors. This study was performed to evaluate long-term results of BCT for patients undergoing surgery first versus chemotherapy. Methods: 2,984 patients underwent BCT with whole breast irradiation from 1987 to 2005. Clinicopathologic and outcomes data were reviewed and comparisons made between surgery first and chemotherapy patients. Results: 2,331 (78%) patients underwent surgery first; 653 (22%) received chemotherapy first. Overall, chemotherapy patients had more adverse clinicopathologic features (Table). 5 and 10-yr local-regional recurrence (LRR)-free survival rates were 97% (95% CI: 96%-98%) and 94% (93%-95%) for surgery first patients. Chemotherapy downstaged patients presenting with clinical stage II/III disease (608/653; 93%) allowing for BCT, and pathologic findings revealed stage II/III disease in only 305/653 (46%) (p&lt;.001). 5 and 10-yr LRR-free survival rates were 93% (91%-95%) and 90% (87%-93%) after chemotherapy. After adjusting for clinical stage at presentation, there were no differences in LRR between surgery first and chemotherapy patients. On multivariate analysis, age&lt;50, clinical stage III, grade 3, ER neg status, associated DCIS on final pathology, and close/positive margins were associated with LRR. Conclusions: LRR after BCT is driven by biologic factors and not the timing of chemotherapy. Chemotherapy downstages a significant number of patients with stage II/III disease allowing appropriately selected patients to achieve high rates of local-regional control with BCT. [Table: see text]
Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation
Authors: Sameh Gaballa, Isabell Ge, Riad O. El Fakih, Jonathan E. Brammer, Sa A. Wang, Dean A. Lee, Demetrios Petropoulos, Kai Cao, Gabriela Rondon, Julianne Chen, Aimee E Hammerstrom, Gheath Al-Atrash, Martin Korbling, Betul Oran, Partow Kebriaei, Sairah Ahmed, Nina Shah, Katayoun Rezvani, David Marin, Qaiser Bashir, Amin M. Alousi, Yago Nieto, Muzaffar H. Qazilbash, Chitra M. Hosing, Uday R. Popat, Elizabeth J. Shpall, Issa F. Khouri, Richard E. Champlin, Stefan O. Ciurea
Journal: Blood (2015)
Carboplatin (Cb), weekly nanoparticle, albumin-bound paclitaxel (wAb), and bevacizumab (Av) neoadjuvant chemotherapy (NAC) in HER2-negative breast cancer (BrCA): A BrUOG study.
Authors: N. Sinclair, M. M. Abu-Khalaf, B. J. Sakr, T. Rizack, D. R. Lannin, J. S. Gass, R. Strenger, V. Bossuyt, M. A. Fenton, L. Harris, W. M. Sikov
Journal: Journal of Clinical Oncology (2011)

e11573 Background: To evaluate CbwAbAv NAC in HER2- BrCA. Methods: 60 patients (pts) with HER2- (IHC 0-1+ or FISH <2.0) invasive BrCA, clinical stage IIA-IIIC, will undergo research biopsies/MRI pre and post “priming” doses of Av or wAb, then receive q3wk Cb AUC 6, wAb 100 mg/m2 + Av 5 mg/kg/week x 12 weeks + (cohort 1)/- (cohort 2) dose-dense doxorubicin and cyclophosphamide (ddAC)Av x 4. Post-op, pts receive Av x 34 weeks; radiation, endocrine Rx, and ddACAv x 4 (cohort 2) at MD discretion. Endpoints include pathologic complete response (pCR - absence of invasive disease in breast + axillary nodes), residual cancer burden (RCB) in non-pCRs, dose delivery and toxicities. Circulating tumor/endothelial cells (CTC/CEC) at baseline and after priming are analyzed using the Veridex platform. Results: 39 pts (median age 47; range 25-69), 21 hormone receptor positive (HR+), 18 triple-negative (TN) have received a median of 11 wAb and 4 Cb doses, with dose reductions in 25% (wAb - neutropenia [ANC]) and 14% (Cb - thrombocytopenia (tcp)). Grade 3/4 toxicities include ANC (43%/39%), tcp (18%/7%), transaminitis, nausea and hypokalemia, with no grade >2 neuropathy. Serious adverse events (SAEs): febrile neutropenia (2), altered mental status, anemia, post-mastectomy tissue necrosis, GI bleed and grade 2 proteinuria. Pathologic responses are tabulated below (Table). At baseline, few pts (19%) had identifiable CTC, which did not correlate with response. Pts with higher CEC levels at baseline (median, 22 vs. 11, p=.087) or after priming (median, 31 vs. 14.5, p=.035) were more likely to achieve RCB 0-1. Conclusions: Neoadjuvant CbwAbAv is generally well tolerated and yields encouraging pathologic responses, especially in TN pts. Differences between cohorts suggest that longer duration NAC or the use of non-cross resistant regimens may improve pCR rate. Higher CEC levels at baseline or after initial therapy may be associated with improved pathologic response. Updated results will be presented. n pCR IA/IB II-III RCB 0-1 RCB 2-3 Total 39 13 (33%) 9 17 21 (54%) 18 Cohort 1 21 (12 TN) 12 (57%) 3 6 15 (71%) 6 Cohort 2 18 (6 TN) 1 (6%) 6 11 6 (33%) 12 HR+ 21 3 (14%) 2 16 6 (29%) 15 TN 18 10 (56%) 7 1 15 (83%) 3
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial
Authors: Guy Young, Peter W. Collins, Ramin Tehranchi, Ampaiwan Chuansumrit, Hideji Hanabusa, Steven R. Lentz, Johnny N. Mahlangu, Evelien Mauser-Bunschoten, Claude Negrier, Johannes Oldenburg, Turkan Patiroglu, Elena Santagostino, Marek Zak, Fara Abdul Karim
Journal: Blood (2014)
Association Between Mitochondrial DNA Haplogroup and Myelodysplastic Syndromes
Authors: Jenny N Poynter, Michaela Richardson, Erica Langer, Anthony Hooten, Michelle A. Roesler, Betsy A. Hirsch, Phuong L. Nguyen, Adina Cioc, Erica Warlick, Julie A Ross
Journal: Blood (2015)